Osteoarthritis, HipNCT05587244
G7 Freedom Constrained Vivacit-E Liners
A study testing Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners in people with Osteoarthritis, Hip and Rheumatoid Arthritis, run by Zimmer Biomet at 10 sites in United States.
Trial summary
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture
- What is being tested?
- Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 202 participants
- Where
- 10 sitesUnited States
- Study dates
- 8 May 2023to Dec 2038
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is 18 to 80 years of age, inclusive
- Patient is skeletally mature
- Patient qualifies for unilateral total hip arthroplasty based on physical exam and medical history including at least one of the following:
- Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
- Rheumatoid arthritis
- High risk for dislocation
Show all 11Show fewer
- Undergoing revision hip arthroplasty
- Correction of functional deformity
- In need of treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
- Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
- Patient, or the patient's legally authorized representative, has participated in the Informed Consent process and is willing and able to sign an IRB approved informed consent
Who cannot join
- Patient is septic, has an active infection or has osteomyelitis at the affected joint
- Patient has significant osteoporosis as defined by treating surgeon
- Patient has metabolic disorder(s) which may impair bone formation
- Patient has osteomalacia
- Patient has distant foci of infections which may spread to the implant site
- Patient has rapid joint destruction, marked bone loss or bone resorption on pre-operative radiographs
Show all 15Show fewer
- Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure
- Patient is undergoing simultaneous bilateral THA
- Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which might jeopardize the outcome of the surgery.
- In the opinion of the investigator, patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
- Patient is known to be pregnant
- The patient is in the vulnerable population group, such as
- a prisoner
- a known alcohol or drug abuser
- mentally incompetent or unable to understand what participation in this study entails
Trial locations and contacts
10 sites in 1 country. Contact the study team or a site near you to ask about taking part.
10 sites in 1 country
United States10 sites
University of Alabama at Birmingham
Birmingham, Alabama, 35205
The Ohio State University
Columbus, Ohio, 43201
University of Florida Board of Trustees
Gainesville, Florida, 32611
The University of Texas Health Science Center of Houston
Houston, Texas, 77030
TOA Research Foundation
Knoxville, Tennessee, 37923
Jersey City Medical Center, Inc
Livingston, New Jersey, 07039
University of Southern California
Los Angeles, California, 90033
West Virginia University
Morgantown, West Virginia, 26506
Medical City Plano
Plano, Texas, 75075
University of Utah
Salt Lake City, Utah, 84108
About this study
Official title: Multicenter, Prospective Post-Market Clinical Follow-Up Study of the G7® Freedom Constrained Vivacit-E® Liners
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.
Read the detailed description
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.
The primary endpoint is defined by the survival of the implant system at 10 years, which is based on removal of the study device and will be determined using the Kaplan-Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to the implant, instrumentation and/or procedure should be specified.
The secondary endpoints are the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs) as well as radiographic outcomes (if available).
The G7 Vivacit-E Freedom Constrained Liner is indicated for use (per IFU) as a component of a total hip prosthesis in primary and revision patients at high risk of dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability, and for whom all other options to constrained acetabular components have been considered.
- Conditions
- Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures, Femoral Neck Fractures, Avascular Necrosis
- Being tested
- Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
- Medical subject headings
- Osteoarthritis, Hip, Arthritis, Rheumatoid, Fractures, Ununited, Hip Fractures, Femoral Neck Fractures, Osteonecrosis, Hip Dislocation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E LinersDevice
Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
| Study group | Role | What they receive |
|---|---|---|
| Total Hip Arthroplasty Treatment Group | Experimental | This study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects. Receives: Device: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival of the study device
Survival (whether or not it is still implanted in the subject) determined using Kaplan Meier method.
Measured: 10 years
Secondary outcomes (10)
Incidence of treatment-emergent Adverse Events (safety)
Safety is assessed by monitoring the frequency and incidence of all adverse events, with particular focus on those that may be related to the study device.
Measured: 10 years
Pain and Functional Performance - Modified Harris Hip Score
The Harris Hip Score evaluates hip function, pain, mobility and daily activity impairment after hip replacement surgery.
The ten items in the Harris hip score consist of answer choices, awarded a number of points. There are four domains evaluated, as follows:
- Pain - 1 item which scores between 0 and 44;
- Function - 7 items, scores are between 0 and 47;
- Deformity - 1 item which scores either 0 or 4;
- Range of motion - 1 item which scores between 0 and 5.
The overall score varies between 0 and 100, where scores closer to 0 are suggestive of impaired hip function and scores closer to 100 indicate positive outcome.
There are four categories of hip function status:
- <70: poor hip status;
- 70 - 79: fair hip status;
- 80 - 89: good hip status;
- 90 - 100: excellent hip status.
Measured: 10 years
Pain and Functional Performance - Oxford Hip Score
"The Oxford Hip Score is patient-reported outcome instrument which contains 12 questions on activities of daily living that assess function and residual pain in patients undergoing total hip replacement surgery.
Grading the Oxford Hip Score 0 to 19-May indicate severe hip arthritis... 20 to 29-May indicate moderate to severe hip arthritis... 30 to 39-May indicate mild to moderate hip arthritis... 40 to 48-May indicate satisfactory joint function..." Oxford Hip Score. (n.d.) Segen's Medical Dictionary. (2011). Retrieved August 19 2022 from https://medical-dictionary.thefreedictionary.com/Oxford+Hip+Score
Each question is scored from 0 to 4 with 4 being the best outcome. This method, when summed, produces overall scores running from 0 to 48 with 48 being the best outcome. The overall score is reached by simply summing the scores received for individual questions. This results in a continuous score ranging from 0 (most severe symptoms) to 48 (least symptoms).
Measured: 10 years
Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)
The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death. Note: no VAS measures will be obtained if completed by phone interview.
Measured: 10 Years
Radiographic Performance evaluating radiolucency at 5 years follow-up
X-rays will be evaluated for radiolucency lines to show the number of subjects with radiolucency. Radiolucency refers to structures that are less dense and permit the x-ray beam to pass through them. Radiolucent structures appear dark or black in the radiographic image.
Measured: 5 Years
Radiographic Performance evaluating osteolysis at 5 years follow-up
X-rays will be evaluated for osteolysis to show the number of subjects with osteolysis. Osteolysis is a progressive condition where bone tissue is destroyed. In this process, bones lose minerals (mostly calcium), softens, degenerates and become weaker.
Measured: 5 Years
Radiographic Performance evaluating atrophy/hypertrophy at 5 years follow-up
X-rays will be evaluated for muscular atrophy/hypertrophy. An increase in total mass of a muscle is referred to as as hypertrophy, whereas a decrease in total mass of a muscle is referred to as atrophy.
Measured: 5 Years
Radiographic Performance evaluating component migration at 5 years follow-up
X-rays will be evaluated for component migration to show the number of subjects with migration. Component migration refers to the presence of the device component gradually moving anteriorly, posteriorly, superiorly, or inferiorly in relation to original placement.
Measured: 5 Years
Radiographic Performance evaluating device fracture at 5 years follow-up
Radiographs will be evaluated (up to 5 years) for evidence of device fracture.
Measured: 5 Years
Radiographic Performance evaluating heterotopic ossification at 5 years follow-up
X-rays will be evaluated for heterotopic ossification to show the number of subjects with heterotopic ossification. Heterotopic ossification refers to the presence of bone in soft tissue where bone normally does not exist (extraskeletal bone).
Measured: 5 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2022
- Study start8 May 2023
- Primary completionDec 2037 (estimated)
- Study completionDec 2038 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Osteoarthritis, HipStudies of the same condition, open and under way.
- More trials run by Zimmer BiometThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Multicenter, Prospective, Non-controlled, Non-randomized, Consecutive series of patients, two cohort study
- Masking
- None (open label)
- Enrolment
- 202 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zimmer Biomet
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Hillary Overholser, Study director, Zimmer Biomet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05587244
- Sponsor's protocol ID
- CMG2021-36H
- Status last verified
- Oct 2025
- First submitted
- 10 Oct 2022
- Last updated
- 20 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicenter, Prospective Post-Market Clinical Follow-Up Study of the G7® Freedom Constrained Vivacit-E® Liners
- ClinicalTrials.gov ID
- NCT05587244
- Acronym / sponsor ID
- CMG2021-36H
- Conditions
- Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures, Femoral Neck Fractures, Avascular Necrosis
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 202 participants (estimated)
- Lead sponsor
- Zimmer BiometIndustry (pharma, biotech, devices)
- Study start
- 8 May 2023 (actual)
- Primary completion
- Dec 2037 (estimated)
- Study completion
- Dec 2038 (estimated)
- First posted
- 20 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.
Detailed description
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.
The primary endpoint is defined by the survival of the implant system at 10 years, which is based on removal of the study device and will be determined using the Kaplan-Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to the implant, instrumentation and/or procedure should be specified.
The secondary endpoints are the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs) as well as radiographic outcomes (if available).
The G7 Vivacit-E Freedom Constrained Liner is indicated for use (per IFU) as a component of a total hip prosthesis in primary and revision patients at high risk of dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability, and for whom all other options to constrained acetabular components have been considered.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Multicenter, Prospective, Non-controlled, Non-randomized, Consecutive series of patients, two cohort study
| Arm | Type | Receives |
|---|---|---|
| Total Hip Arthroplasty Treatment Group | Experimental | Device: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E LinersThis study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Patient is 18 to 80 years of age, inclusive
- Patient is skeletally mature
- Patient qualifies for unilateral total hip arthroplasty based on physical exam and medical history including at least one of the following:
- Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
- Patient, or the patient's legally authorized representative, has participated in the Informed Consent process and is willing and able to sign an IRB approved informed consent
Key exclusion criteria (15 listed)
- Patient is septic, has an active infection or has osteomyelitis at the affected joint
- Patient has significant osteoporosis as defined by treating surgeon
- Patient has metabolic disorder(s) which may impair bone formation
- Patient has osteomalacia
- Patient has distant foci of infections which may spread to the implant site
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E LinersPrimary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners | Device | Total Hip Arthroplasty Treatment Group |
Primary outcome
Survival of the study device
Time frame: 10 years
Survival (whether or not it is still implanted in the subject) determined using Kaplan Meier method.
10 secondary outcomes
Incidence of treatment-emergent Adverse Events (safety)
Time frame: 10 years
Pain and Functional Performance - Modified Harris Hip Score
Time frame: 10 years
Pain and Functional Performance - Oxford Hip Score
Time frame: 10 years
Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)
Time frame: 10 Years
Radiographic Performance evaluating radiolucency at 5 years follow-up
Time frame: 5 Years
Radiographic Performance evaluating osteolysis at 5 years follow-up
Time frame: 5 Years
Radiographic Performance evaluating atrophy/hypertrophy at 5 years follow-up
Time frame: 5 Years
Radiographic Performance evaluating component migration at 5 years follow-up
Time frame: 5 Years
Radiographic Performance evaluating device fracture at 5 years follow-up
Time frame: 5 Years
Radiographic Performance evaluating heterotopic ossification at 5 years follow-up
Time frame: 5 Years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Osteoarthritis, Hip
Not yet recruiting
Effects of Low-Load Blood Flow Restriction Resistance Training With and Without Hip Abductor Strengthening in Patients With Knee Osteoarthritis.(BFR)
Knee Osteoarthritis
Recruiting
FRONT Block for Quality of Recovery After Total Hip Arthroplasty
Osteoarthritis of the Hip, Postoperative Pain
RecruitingObservational study
Post-Market Clinical Follow-up of Intra-Articular Hyaluronic Acid in Hip Osteoarthritis
Hip OA
Not yet recruitingObservational study
Clinical Validation of SMARTDIAGO for Remote Functional Assessment of Musculoskeletal Conditions
Knee Osteoarthristis, Hip Osteoarthritis
RecruitingObservational study
Z1 Hip System: Post-Market Clinical Follow Up Study
Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hillary Overholser study director
Zimmer Biomet
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners in people with Osteoarthritis, Hip and Rheumatoid Arthritis, run by Zimmer Biomet at 10 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 20 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival of the study device (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2025.